Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Non-Current Debt: 2022-2024

Historic Non-Current Debt for UroGen Pharma (URGN) over the last 3 years, with Dec 2024 value amounting to $121.7 million.

  • UroGen Pharma's Non-Current Debt rose 0.33% to $122.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $122.1 million, marking a year-over-year increase of 0.33%. This contributed to the annual value of $121.7 million for FY2024, which is 23.52% up from last year.
  • According to the latest figures from FY2024, UroGen Pharma's Non-Current Debt is $121.7 million, which was up 23.52% from $98.6 million recorded in FY2023.
  • UroGen Pharma's Non-Current Debt's 5-year high stood at $121.7 million during FY2024, with a 5-year trough of $97.5 million in FY2022.
  • In the last 3 years, UroGen Pharma's Non-Current Debt had a median value of $98.6 million in 2023 and averaged $105.9 million.
  • Data for UroGen Pharma's Non-Current Debt shows a peak YoY climbed of 23.52% (in 2024) over the last 5 years.
  • UroGen Pharma's Non-Current Debt (Yearly) stood at $97.5 million in 2022, then climbed by 1.04% to $98.6 million in 2023, then rose by 23.52% to $121.7 million in 2024.